Abstract:Abstract Development of an electrochemical diagnostic test would provide quantitative detection of biomarkers characteristic of clinical serum samples that may facilitate early detection and triage of glioma patients in the clinical setting. Today, 32 individuals will receive a confirmatory diagnosis of a brain tumor in the UK, equivalent to 3% of all patients diagnosed with cancer annually. Implications for patients and families are tragic, brain cancer is responsible for >5,000 mortalities annually in the UK, with 20.1 mean years of life lost to the disease per patient, greater than any other cancer. Presently, ~22% of brain cancer patients receive diagnosis through GP referral, with over a third of patients attending their health practice on five occasions prior to diagnosis. Brain tumor symptoms are diverse and often non-specific in the absence of epileptic seizures, with an extremely poor positive predictive value. Consequently, suspected patients experience significant diagnostic delays, with significant time spent in primary care settings. Heightened symptoms often translates to emergency presentation, where >60% of brain cancer patients currently receive diagnosis, associated with reduced survival compared to non-emergency pathways. Hence, earlier detection of brain cancer patients is a clinical need within primary care settings to prevent significant diagnostic delays and improve patient outcomes. Introduction of a widespread screening program with medical imaging modalities is not economically viable for early detection of brain cancer given high test costs and low incidence in the general population. However, a recent health economic study suggested a blood-based test may prove cost saving to NHS services if employed to triage brain tumor patients for medical imaging in primary and secondary care. Blood is fundamental to physiological function of cells and their perpetual interaction provides a rich source of endogenous molecules that may reflect biochemical events of gliomagenesis. Our current work towards development of a blood-based electrochemical platform for brain cancer focuses on screening of clinical serum samples for a large panel of cytokines from confirmed patients with glioma tumor types. Thereafter, our work demonstrates electrochemical detection of elevated cytokine biomarkers identified within our serum samples. Previously, we demonstrated the potential of this platform technology for early detection of Hodgkin lymphoma, with successful discrimination between cancerous and non-cancerous patient samples, which we now hope to extend to early detection of brain cancer. Implementation of a low-cost, point-of-care triage blood test for brain cancer would have significant clinical and economical benefits, ultimately facilitating the promotion of early detection strategies in primary care to enable timely cancer diagnosis and improve patient outcomes. Citation Format: Christopher Rinaldi, Ashton G. Theakstone, Damion Corrigan, Paul Brennan, Matthew J. Baker. Towards an electrochemical serum-based platform for early diagnosis and stratification of glioma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2598.

Plasma alpha B crystallin as potential biomarker for predicting pre-operative seizures in glioma

Predictive Value of Serum Caspase-Cleaved Cytokeratin-18 Concentrations after Acute Intracerebral Hemorrhage

A predicted model for postoperative seizure outcomes after the surgical resection of supratentorial cavernous malformations.

Plasma-Derived Extracellular Vesicles Reveal Galectin-3 Binding Protein as Potential Biomarker for Early Detection of Glioma

Association of preoperative seizures with reduced expression of soluble CD163, an M2 macrophage marker, in the cerebrospinal fluid in isocitrate dehydrogenase wild-type glioblastoma

New-Onset Postoperative Seizures in Patients With Diffuse Gliomas: A Risk Assessment Analysis

Seizure Burden and Clinical Risk Factors in Glioma‐Related Epilepsy: Insights From MRI Voxel‐Based Lesion‐Symptom Mapping

The Potential of Seizure to Predict Prognosis in Glioblastoma Patients: A retrospective Study

Soluble cytotoxic T-lymphocyte-associated antigen 4 (sCTLA-4) as a potential biomarker for diagnosis and evaluation of the prognosis in Glioma

Proteomic Analysis of Cerebrospinal Fluid: Toward the Identification of Biomarkers for Gliomas.

Biom-72. Integration Of Ultrasensitive Electroluminescent Immunoassay And Cell-Free Dnamethylation Analysis For Non-Invasive Monitoring Of Adult Diffuse Gliomas

IL-6 is associated with poor seizure control in low-grade glioma patients undergoing primary resection

Resective surgery for patients with frontal lobe diffuse low-grade glioma-related epilepsy: predictors of seizure outcomes

Radiomics for the Prediction of Epilepsy in Patients With Frontal Glioma

Plasma Glial Fibrillary Acidic Protein (GFAP) as a Biomarker of Acute Focal Brain Injury

Abstract 2598: Towards an electrochemical serum-based platform for early diagnosis and stratification of glioma

Urinary biomarker discovery in gliomas using mass spectrometry-based clinical proteomics

High expression of cystine–glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma

Pre-operative predictors of post-operative seizure control in low-grade glioma: a systematic review and meta-analysis

Serum Protein Fingerprinting Coupled with Artificial Neural Network Distinguishes Glioma from Healthy Population or Brain Benign Tumor

Prevalence and risk factors of early postoperative seizures in patients with glioma: a systematic review and meta-analysis